An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2015
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 17 Jul 2008 The expected completion date for this trial is now 1 Nov 2008.
- 17 Jun 2008 Actual patient number (42) added as reported by ClinicalTrials.gov.
- 17 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.